IPP Bureau
Lupin receives USFDA approval for Tolvaptan Tablets
By IPP Bureau - April 24, 2025
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Lupin Diagnostics achieves NABL accreditation for all greenfield labs
By IPP Bureau - April 24, 2025
The 27 greenfield labs across the country ensure timely and accurate reporting
Wanbury to implement the SAP S/4 HANA private cloud platform
By IPP Bureau - April 24, 2025
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
Caplin Steriles gets USFDA approval for Phytonadione Injectable Emulsion
By IPP Bureau - April 24, 2025
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
Eugia Pharma receives USFDA approval for Dasatinib Tablets
By IPP Bureau - April 24, 2025
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion
By IPP Bureau - April 24, 2025
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
DHL Express and Sai Life Sciences sign GoGreen Plus partnership to make pharma deliveries more sustainable
By IPP Bureau - April 24, 2025
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Laurus Labs Q4 FY25 PAT up 208% to Rs. 234 Cr
By IPP Bureau - April 24, 2025
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Nureca receives approval for new manufacturing facility
By IPP Bureau - April 23, 2025
This unit will focus on the manufacturing of health and wellness equipment
Cosmo First to acquire veterinary clinic
By IPP Bureau - April 23, 2025
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
WHO prequalifies Syngenta’s innovative insecticide Sovrenta
By IPP Bureau - April 23, 2025
A new weapon in the global fight against malaria
Paras Healthcare introduces radiation oncology facility at Ranchi
By IPP Bureau - April 23, 2025
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
Gujarat CM Bhupendra Patel inaugurates 217-bed cancer hospital in Ahmedabad
By IPP Bureau - April 22, 2025
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer
By IPP Bureau - April 22, 2025
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
